Literature DB >> 28373060

Cross-talk between the CK2 and AKT signaling pathways in cancer.

Maria Ruzzene1, Jessika Bertacchini2, Alex Toker3, Sandra Marmiroli4.   

Abstract

CK2 and AKT display a high degree of cross-regulation of their respective functions, both directly, through physical interaction and phosphorylation, and indirectly, through an intense cross-talk of key downstream effectors, ultimately leading to sustained AKT activation. Being CK2 and AKT attractive targets for therapeutic intervention, here we would like to emphasize how AKT and CK2 might influence cell fate through their complex isoform-specific and contextual-dependent cross-talk, to the extent that such functional interplay should be considered when devising therapies that target one or both these key signaling kinases.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28373060     DOI: 10.1016/j.jbior.2017.03.002

Source DB:  PubMed          Journal:  Adv Biol Regul        ISSN: 2212-4926


  15 in total

Review 1.  Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.

Authors:  Chandrika Gowda; Mario Soliman; Malika Kapadia; Yali Ding; Kimberly Payne; Sinisa Dovat
Journal:  Adv Biol Regul       Date:  2017-06-13

2.  Polymerase III transcription is necessary for T cell priming by dendritic cells.

Authors:  Marisa Reverendo; Rafael J Argüello; Christine Polte; Jan Valečka; Voahirana Camosseto; Nathalie Auphan-Anezin; Zoya Ignatova; Evelina Gatti; Philippe Pierre
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-21       Impact factor: 11.205

3.  Role of the RNA-binding protein La in cancer pathobiology.

Authors:  Gunhild Sommer; Tilman Heise
Journal:  RNA Biol       Date:  2020-07-20       Impact factor: 4.652

4.  Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.

Authors:  Yixuan Ma; Sina Sender; Anett Sekora; Weibo Kong; Peter Bauer; Najim Ameziane; Susann Krake; Mandy Radefeldt; Ruslan Al-Ali; Frank Ulrich Weiss; Markus M Lerch; Alisha Parveen; Dietmar Zechner; Christian Junghanss; Hugo Murua Escobar
Journal:  Int J Mol Sci       Date:  2022-04-16       Impact factor: 6.208

Review 5.  Nuclear phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular, and fertility disorders.

Authors:  Stefano Ratti; Matilde Y Follo; Giulia Ramazzotti; Irene Faenza; Roberta Fiume; Pann-Ghill Suh; James A McCubrey; Lucia Manzoli; Lucio Cocco
Journal:  J Lipid Res       Date:  2018-10-04       Impact factor: 5.922

6.  CK2 Controls Th17 and Regulatory T Cell Differentiation Through Inhibition of FoxO1.

Authors:  Sara A Gibson; Wei Yang; Zhaoqi Yan; Hongwei Qin; Etty N Benveniste
Journal:  J Immunol       Date:  2018-06-11       Impact factor: 5.422

Review 7.  Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Authors:  Christian Borgo; Claudio D'Amore; Stefania Sarno; Mauro Salvi; Maria Ruzzene
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

8.  The importance of negative determinants as modulators of CK2 targeting. The lesson of Akt2 S131.

Authors:  Jordi Vilardell; Cristina Girardi; Oriano Marin; Giorgio Cozza; Lorenzo A Pinna; Maria Ruzzene
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

9.  Activation of Casein Kinase II by Gallic Acid Induces BIK-BAX/BAK-Mediated ER Ca++-ROS-Dependent Apoptosis of Human Oral Cancer Cells.

Authors:  Meng-Liang Lin; Shih-Shun Chen
Journal:  Front Physiol       Date:  2017-09-29       Impact factor: 4.566

Review 10.  Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.

Authors:  Sabrina Manni; Marilena Carrino; Francesco Piazza
Journal:  J Hematol Oncol       Date:  2017-10-02       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.